Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$291 Mln
P/E Ratio
--
P/B Ratio
1.42
Industry P/E
--
Debt to Equity
0.22
ROE
-0.49 %
ROCE
-38.2 %
Div. Yield
0 %
Book Value
3.44
EPS
-1.38
CFO
$-252.18 Mln
EBITDA
$-352.32 Mln
Net Profit
$-396.69 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Personalis (PSNL)
| -44.81 | -12.12 | -33.26 | 157.26 | -22.68 | -18.12 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Personalis (PSNL)
| 172.98 | 6.06 | -86.12 | -61.02 | 235.87 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD),... therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California. Address: 6600 Dumbarton Circle, Fremont, CA, United States, 94555 Read more
President, CEO & Director
Mr. Christopher M. Hall
President, CEO & Director
Mr. Christopher M. Hall
Headquarters
Fremont, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Personalis Inc (PSNL) stood at $ 270 Mln as on 31-Dec-24
The share price of Personalis Inc (PSNL) is $3.19 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Personalis Inc (PSNL) has given a return of -22.68% in the last 3 years.
Personalis Inc (PSNL) has a market capitalisation of $ 291 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Personalis Inc (PSNL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Personalis Inc (PSNL) and enter the required number of quantities and click on buy to purchase the shares of Personalis Inc (PSNL).
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California. Address: 6600 Dumbarton Circle, Fremont, CA, United States, 94555
The CEO & director of Mr. Christopher M. Hall. is Personalis Inc (PSNL), and CFO & Sr. VP is Mr. Christopher M. Hall.
There is no promoter pledging in Personalis Inc (PSNL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Personalis Inc. (PSNL) | Ratios |
|---|---|
|
Return on equity(%)
|
-48.91
|
|
Operating margin(%)
|
-96.01
|
|
Net Margin(%)
|
-96.06
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Personalis Inc (PSNL) was $0 Mln.
$-0.10
(
